Andrew S. Levey
Andrew S. Levey | |
|---|---|
.jpg) Andrew S. Levey, MD at Tufts Medical Center in 2021 | |
| Born | September 16, 1950 |
| Alma mater | |
| Known for | Developing estimates of Renal function to define and stage Chronic Kidney Disease and apply them in clinical practice, research and public health. |
| Scientific career | |
| Fields | Nephrology, Epidemiology |
| Institutions | Tufts University School of Medicine, Tufts Medical Center |
Andrew S. Levey (born September 16, 1950) is an American nephrologist who transformed chronic kidney disease (CKD) clinical practice, research, and public health by developing equations to estimate glomerular filtration rate (GFR) (renal function), and leading the global standardization of CKD definition and staging.
Education and career
[edit]Levey graduated from the University of Chicago in 1972 with a Bachelor of Arts in Biological Sciences and graduated as a Doctor of Medicine (MD) in 1976 at the Boston University School of Medicine. He became a Professor of Medicine in the Tufts University School of Medicine in 1994, and was Chief of the Division of Nephrology from 1999 to 2017.
Contributions
[edit]Levey is known for developing the most widely used equations to estimate GFR (renal function) globally. He pioneered work with the MDRD Study Equation, [1] led the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI), which pooled measured kidney function CKD data from studies all over the world to develop equations to estimate kidney function from serum creatinine, cystatin C, and panels of metabolites and low-molecular-weight proteins.[2][3][4] The 2009 creatinine equation with race and the 2021 creatinine equation without race to replace the 2009 equation are shown below:
![{\displaystyle \mathrm {eGFR} =141\ \times \ \mathrm {\min(SCr/k,1)} ^{a}\ \times \ \mathrm {\max(SCr/k,1)} ^{-1.209}\ \times \ 0.993^{\text{Age}}\ \times {\text{[1.018 if Female]}}\ \times {\text{[1.159 if Black]}}\ }](https://wikimedia.org/api/rest_v1/media/math/render/svg/e695776a5827ef76b340344758106f09888735e6)
![{\displaystyle \mathrm {eGFR} =142\ \times \ \mathrm {\min(SCr/k,1)} ^{a}\ \times \ \mathrm {\max(SCr/k,1)} ^{-1.200}\ \times \ 0.9938^{\text{Age}}\ \times {\text{[1.012 if Female]}}\ }](https://wikimedia.org/api/rest_v1/media/math/render/svg/fa13dfed62861a1810ff76c5900f647fc5b857d7)
For both equations, α is -0.241 for females and -0.302 for males; min indicates minimum of Scr/k or 1, and max indicates maximum of Scr/k or 1
Levey is an authority on clinical practice guidelines in kidney disease. He chaired the U.S. National Kidney Foundation Kidney Disease Outcome Quality Initiative (KDOQI) Clinical Practice Guideline Workgroup on “Chronic Kidney Disease: Evaluation, Classification and Risk Stratification”[5]. The recommendations from this workgroup transformed the way Kidney Disease was defined and staged globally. The guideline has been cited over 10,000[6] times in subsequent research publications. He led multiple KDOQI and Kidney Disease Improving Global Outcomes (KDIGO)[7] guidelines which advanced the global recognition and care for CKD,[8][9][10][11] hypertension,[12] acute kidney injury,[7] living kidney donor evaluation,[13] and nomenclature.[14]
Levey was a founding member of the Chronic Kidney Disease Prognosis Consortium (CKDPC),[15] which includes over 80 cohorts and 10 million[16] participants and has informed multiple clinical practice guidelines and regulatory policies.
Levey led the U.S. National Kidney Foundation task force on cardiovascular disease in chronic kidney disease, which led to the recognition by the American Heart Association of CKD as a risk factor for cardiovascular disease.[17][18]
Levey co-chaired the U.S. Centers for Disease Control and Prevention expert panel to develop comprehensive public health strategies for preventing the development, progression, and complications of CKD.[19]
Levey led scientific workshops sponsored by the U.S. National Kidney Foundation in collaboration with the U.S. Food and Drug Administration and European Medicines Association for the evaluation of Renal function as surrogate endpoints for clinical trials of kidney disease progression.[20][21][22]
Levey was editor-in-chief for American Journal of Kidney Diseases, the official journal of the U.S. National Kidney Foundation, from 2007-2016.
Awards
[edit]- Tufts University School of Medicine: Dean’s Award for Excellence in Teaching (1986), Dr. Gerald J. and Dorothy R. Friedman Professor of Medicine (1999), Distinguished Faculty Award (2004), Dr. Gerald J. and Dorothy R. Friedman Professor of Medicine Emeritus (2017), Zucker Family Prize for Research (2019)
- Tufts University: Faculty Recognition Award (1999)
- Boston University School of Medicine: Distinguished Alumnus (2013)
- National Kidney Foundation: President's Award (1998), Garabed Eknoyan Award (2002) and David M. Hume Award (2012)
- American Society of Nephrology: Belding H. Scribner Award (2013)
- Association of American Physicians: Member (2016)
- European Renal Association/European Dialysis and Transplant Association: Honorary Membership (2020)
- Web of Science High Cited Researcher Thomson Reuters and Clarivate Analytics (2014-2021)
Personal
[edit]Levey is married to Roberta Falke, MD. In 2009 he donated a kidney to her via a 3-pair transplant[23].
References
[edit]- ^ Levey, Andrew (1999). "A More Accurate Method to Estimate Glomerular Filtration Rate From Serum Creatinine: A New Prediction Equation. Modification of Diet in Renal Disease Study Group". Ann Intern Med. 130 (6): 461–70. doi:10.7326/0003-4819-130-6-199903160-00002. PMID 10075613. S2CID 1902375.
- ^ Levey, Andrew (2009). "A new equation to estimate glomerular filtration rate". Ann Intern Med. 150 (9): 604–12. doi:10.7326/0003-4819-150-9-200905050-00006. PMC 2763564. PMID 19414839.
- ^ Inker, Lesley (2012). "Estimating Glomerular Filtration Rate from Serum Creatinine and Cystatin C". New England Journal of Medicine. 367 (367): 20–29. doi:10.1056/NEJMoa1114248. PMC 4398023. PMID 22762315.
- ^ Inker, Lesley (2021). "New Creatinine- and Cystatin C–Based Equations to Estimate GFR without Race". New England Journal of Medicine. 385 (19): 1737–1749. doi:10.1056/NEJMoa2102953. PMC 8822996. PMID 34554658. S2CID 237608965.
- ^ Levey, Andrew (2003). "National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification". Ann Intern Med. 139 (2): 137–47. doi:10.7326/0003-4819-139-2-200307150-00013. PMID 12859163. S2CID 11973331.
- ^ Levey, Andrew (2002), "K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification", American Journal of Kidney Diseases, 39 (2 SUPPL. 1), University of Minnesota: i–ii+S1–S266, PMID 11904577
- ^ a b Levey, Andrew (2012). "KDIGO Clinical Practice Guideline for Acute Kidney Injury" (PDF). Ann Intern Med. 2 (1). doi:10.1038/kisup.2012.1.
- ^ Levey, Andrew (2002). "Clinical Practice Guidelines For Chronic Kidney Disease: Evaluation, Classification and Stratification" (PDF). Ann Intern Med. 39 (1): S1–S266.
- ^ Levey, Andrew (2005). "Definition and Classification of Chronic Kidney Disease:A Position Statement From Kidney Disease:Improving Global Outcomes(KDIGO)". Kidney International. 67 (6): 2089–2100. doi:10.1111/j.1523-1755.2005.00365.x. PMID 15882252.
- ^ Levey, Andrew (2011). "The Definition, Classification, and Prognosis of Chronic Kidney Disease: A KDIGO Controversies Conference Report". Ann Intern Med. 80 (1): 17–28. doi:10.1038/ki.2010.483. PMID 21150873.
- ^ Levey, Andrew (2007). "Chronic Kidney Disease as a Global Public Health Problem: Approaches and Initiatives - A Position Statement From Kidney Disease Improving Global Outcomes". Ann Intern Med. 72 (3): 247–59. doi:10.1038/sj.ki.5002343. PMID 17568785.
- ^ Levey, Andrew (2004). "K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease". American Journal of Kidney Diseases. 5 (1): S1-290. PMID 15114537.
- ^ Levey, Andrew (2017). "KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors". Transplantation. 101 (8S): S1–S109. doi:10.1097/TP.0000000000001769. PMC 5540357. PMID 28742762.
- ^ Levey, Andrew (2020). "Nomenclature for Kidney Function and Disease: Report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference". Kidney International. 97 (6): 1117–1129. doi:10.1016/j.kint.2020.02.010. hdl:1765/128502. PMID 32409237.
- ^ "Chronic Kidney Disease Prognosis Consortium (CKD-PC)". CKD Prognosis Consortium. Retrieved May 5, 2020.
- ^ "Participating Cohorts". CKD Prognosis Consortium. Retrieved May 24, 2020.
- ^ Levey, Andrew (1998). "Controlling the Epidemic of Cardiovascular Disease in Chronic Renal Disease: What Do We Know? What Do We Need to Learn? Where Do We Go From Here? National Kidney Foundation Task Force on Cardiovascular Disease". American Journal of Kidney Diseases. 32 (5): 853–906. doi:10.1016/s0272-6386(98)70145-3. PMID 9820460.
- ^ Levey, Andrew (2003). "Kidney Disease as a Risk Factor for Development of Cardiovascular Disease: A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention". Circulation. 108 (17): 2154–69. doi:10.1161/01.CIR.0000095676.90936.80. PMID 14581387. S2CID 2530900.
- ^ Levey, Andrew (2009). "Comprehensive Public Health Strategies for Preventing the Development,Progression, and Complications of CKD: Report of an Expert Panel Convened by the Centers for Disease Control and Prevention". American Journal of Kidney Diseases. 53 (3): 522–535. doi:10.1053/j.ajkd.2008.11.019. PMID 19231739.
- ^ Levey, Andrew (2009). "Proteinuria as a Surrogate Outcome in CKD: Report of a Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration". American Journal of Kidney Diseases. 54 (2): 205–26. doi:10.1053/j.ajkd.2009.04.029. PMID 19577347.
- ^ Levey, Andrew (2014). "GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration". American Journal of Kidney Diseases. 64 (6): 821–35. doi:10.1053/j.ajkd.2014.07.030. PMID 25441437.
- ^ Levey, Andrew (2020). "Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency". American Journal of Kidney Diseases. 75 (1): 84–104. doi:10.1053/j.ajkd.2019.06.009. PMID 31473020.
- ^ English, Bella (March 28, 2010). "Harvesting hope from a giving tree". Archived from the original on April 1, 2022. Retrieved May 24, 2020.
{{cite news}}: CS1 maint: bot: original URL status unknown (link)
External links
[edit]- Andrew S. Levey publications indexed by Google Scholar
| Authority control databases: Academics |
|---|
